Advances in Osteosarcoma in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2005
Antony S. Moore, MVSc, DACVIM (Oncology)
Co-Director, Veterinary Oncology Consultants, Wauchope, NSW; Adjunct Professor, Institute of Veterinary Sciences, Massey University, New Zealand

Appendicular Osteosarcoma in dogs

Abstract

Combinations of surgery and chemotherapy make osteosarcoma one of the most treatable cancers in dogs. Advances in the last 15 years have led to approximately 500% improvement in survival rates one year after amputation, and more than 1000% for 2-year survival rates, when compared to amputation alone. Amputation or limb salvage is palliative for pain but should be combined with chemotherapy for improvement in survival. Cisplatin, carboplatin and doxorubicin are the most active chemotherapy agents. Radiation therapy offers palliative pain relief if amputation is not an option.

Epidemiology

Giant-breed and large-breed dogs are more likely to develop osteosarcoma than dogs that weigh less than 10 kg. Rapid early growth and increase in stress on weight-bearing limbs may explain why the risk is particularly associated with limb length.1 Osteosarcoma can affect dogs of any age, although most are middle-aged to old animals with a median age of 8 years.

Osteosarcomas most commonly affects the metaphysis of the appendicular skeleton; the most common sites are the distal radius and the proximal humerus ("away from the elbow") and the proximal tibia and distal femur ("toward the knee").

Previous fractures and/or the use of metal implants have been associated with the occurrence of osteosarcoma years later. A large, recent study showed there was no evidence for such an association.2

Staging and Diagnosis

Dogs with a suspected primary bone tumour should have high-detail radiographs of the lesion. In addition, routine blood work and urinalysis should be performed. Although pulmonary metastases are rarely detectable at the time of diagnosis, thoracic radiographs still should be taken. Right and left lateral views and a dorsoventral view should be obtained. Dogs with clinically detectable pulmonary metastases have a poor prognosis, with or without treatment. Osteosarcomas frequently include areas of cartilage and fibrous tissue as well as osteoid and are often surrounded by new bone. For these reasons, a histopathologic diagnosis of chondrosarcoma, fibrosarcoma, or "reactive" bone should be considered suspect and further samples obtained at definitive surgery should be submitted for histopathologic examination.

Treatment

Surgery

Amputation eliminates the primary tumour, which provides pain relief with little to no reduction in mobility and quality of life for the dog. Surgical treatment of osteosarcoma by amputation is palliative but rarely increases survival and dogs with appendicular osteosarcoma should be given chemotherapy. The median survival for dogs treated by amputation alone, is about 4 months, and only 10% of dogs are alive one year after surgery.

Limb-sparing surgery is important in human patients, for whom cosmetic appearance and function are impaired by amputation. Limb salvage is not an option for large lesions that involve more than 50% of the bone, or tumours that invade adjacent soft tissue, as these are not easily resectable. Function is poor when tumours of the hindlimb or proximal humerus are treated by limb salvage.3 Another form of limb salvage surgery has been recently reported. This approach combines a surgery to resect local tumour and limb salvage using bone transport osteogenesis.4

Palliative Radiation Therapy

If owners refuse definitive treatment for their pet with osteosarcoma or if an animal is not considered an eligible candidate for amputation or limb sparing, consideration may be given to palliation with radiation therapy. Coarse fractionation of radiation to be delivered in weekly fractions of 8 to 10 Gy has been reported to palliate pain for dogs with osteosarcoma. Improved limb function was seen in approximately 75% of the dogs treated with either 10 Gy on days 0, 7 and 21 of a 3-week protocol, or 8 Gy on days 0 and 7. Improvement lasted for a median of 2 months regardless of the protocol and toxicities were rare.5 A potential risk of pain relief is increased use of the limb leading to a stress-induced pathologic fracture.

Chemotherapy

Survival of dogs with osteosarcoma can be significantly prolonged by adjuvant chemotherapy. Cisplatin markedly improves median survival times to between 180 and 400 days and 1-year survival rates to between 30% and 62%; 2-year survival rates are between 7% and 21%. Doxorubicin prolonged survival in dogs treated by amputation and five bi-weekly doses (30 mg/ m2) with similar results to those achieved with cisplatin. If chemotherapy with doxorubicin is being considered postoperatively, a baseline echocardiogram should be obtained. Decreased cardiac contractility, even in a dog without clinical signs of heart disease, should prompt the clinician to consider alternative chemotherapy. Cardiac screening is particularly important in breeds of dogs that are known to have congenital cardiomyopathy, such as Doberman pinschers and boxers. Combinations of cisplatin and doxorubicin, alternating every 21 days for two cycles, gave a median survival that is comparable to cisplatin chemotherapy alone. 47% of 102 dogs treated with the cisplatin and doxorubicin given on the same day survived 1 year after surgery, 28% were alive 2 years after surgery, and 16% were alive 3 years after amputation and chemotherapy.6 Carboplatin (300 mg/m2 IV) given adjunctively after amputation gave a median survival of about 11 months; 35.4% of the dogs were alive one year after surgery.7 Carboplatin seems to be as effective as cisplatin in treating canine appendicular osteosarcoma, but this drug is not renal toxic and therefore does not require fluid diuresis, which makes carboplatin an easier drug to administer for many private practitioners.

Timing of chemotherapy: The best time after amputation to start chemotherapy is a compromise between allowing time for recovery from surgery, and not allowing time for micrometastases to grow. In one study, chemotherapy was delayed for either 2 days or 10 days after amputation. No difference in survival was seen regardless of the delay, but there was increased toxicity seen in the dogs treated 2 days after surgery.6 Most oncologists agree a delay of two weeks between surgery and starting chemotherapy is acceptable.

Prognostic Factors

Serum ALP: Three studies have demonstrated an association between elevated serum alkaline phosphatase levels at the time of diagnosis and poor survival after amputation for osteosarcoma. High total alkaline phosphatase (ALP) levels, greater than 110 U/L were associated with shorter survival times; 5.5 months versus 12.5 months for dogs with normal serum ALP. Bone ALP levels may be even more powerful in their ability to predict survival in dogs with osteosarcoma.8,9,10

Grade: A recent study suggested that histologically high-grade tumours were associated with a worse prognosis.10 Mitotic rate may be the most important.

Age: In one study, age at time of diagnosis was important for determining survival in dogs treated with amputation alone. Dogs between the ages of 7 and 10 years had the longest survival times; both old and young dogs fared less well.

References

1.  Ru G, et al: Host-reduced risk factors for canine osteosarcoma. Vet.J. 1998;156:31-39.

2.  Li XQ, et al: Relationship between metallic implants and cancer: A case-control study in a canine population. Vet.Comp.Orthopaedics and Traumatology 1993; 2:70-74.

3.  Kuntz CA, et al: Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet.Surg. 1998; 27:417-422.

4.  Degna MT, et al: Bone transport osteogenesis for limb salvage. Vet.Comp.Orthopaedics and Traumatology 2000; 13:18-22.

5.  McEntee MC, et al: Palliative radiotherapy for canine appendicular osteosarcoma. Vet.Radiol.Ultrasound 1993; 34:367-370.

6.  Berg J, et al: Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997; 79:1343-1350.

7.  Bergman PJ, et al: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991to 1993). J.Vet. Intern. Med. 1996; 10:76-81.

8.  Ehrhart N, et al: Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J.Am.Vet Med.Assoc. 1998; 213:1002-1006.

9.  Garzotto CK et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J.Vet. Intern. Med. 2000; 14:587-592.

10. Kirpensteijn J et al. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol. 2002; 39:240-246.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Antony S. Moore, MVSc, DACVIM (Oncology)
England


MAIN : Oncology : Advances in Osteosarcoma
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27